KLRS
Kalaris Therapeutics IncNASDAQHealthcare$5.79-2.44%ClosedMarket Cap: $108.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.68
P/S
0.00
EV/EBITDA
-0.27
DCF Value
$6.25
FCF Yield
-39.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-73.1%
ROA
-35.7%
ROIC
-41.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-10.8M | $-10.0M | $-0.44 | — |
| FY 2025 | $0.00 | -Infinity% | $-46.2M | $-43.4M | $-2.85 | — |
| Q3 2025 | $0.00 | NaN% | $-12.7M | $-11.9M | $-0.64 | — |
| Q2 2025 | $0.00 | NaN% | $-12.3M | $-11.3M | $-0.61 | — |
| Q1 2025 | $0.00 | NaN% | $-10.4M | $-10.2M | $-2.52 | — |
| Q4 2024 | $0.00 | NaN% | $-19.5M | $-18.3M | $-3.64 | — |
| FY 2024 | $0.00 | NaN% | $-55.3M | $-58.8M | $-11.73 | — |
| Q3 2024 | $0.00 | NaN% | $-37.8M | $-38.1M | $-7.64 | — |
| Q2 2024 | $0.00 | NaN% | $-4.2M | $-5.7M | $-1.13 | — |
| Q1 2024 | $0.00 | NaN% | $-2.6M | $-3.4M | $-0.68 | — |
| Q4 2023 | $0.00 | NaN% | $-3.5M | $-3.5M | $-0.70 | — |
| FY 2023 | $0.00 | NaN% | $-13.5M | $-14.7M | $-42.09 | — |